Lukas Biomedical

Lukas Biomedical Interest Coverage

The Interest Coverage Ratio of Lukas Biomedical (6814.TWO) as of Oct 27, 2026 is -35.73. In the previous year, Interest Coverage Ratio was -14.61 — a change of 144.57% (lower).

Interest Coverage

-35.73

YoY

144.57%

Last updated:

Interest Coverage Ratio of Lukas Biomedical is 2024 -35.73 . Interest Coverage Ratio of Lukas Biomedical was 2023 -14.61 . It decreases by 144.57% lower compared to the previous year.

The Lukas Biomedical Interest Coverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Coverage
Date
Interest Coverage
Jan 1, 2017
-1.04 TWD
Jan 1, 2018
-2.00 TWD
Jan 1, 2019
-1.43 TWD
Jan 1, 2020
-1.36 TWD
Jan 1, 2021
-9.85 TWD
Jan 1, 2022
-17.02 TWD
Jan 1, 2023
-14.61 TWD
Jan 1, 2024
-35.73 TWD
The Lukas Biomedical Interest Coverage history
YEARInterest CoverageYoY
-35.73+144.57%
-14.61-14.19%
-17.02+72.83%
-9.85+624.33%
-1.36-5.12%
-1.43-28.41%
-2.00+91.73%
-1.04—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lukas Biomedical Stock analysis

What does Lukas Biomedical do? Lukas Biomedical, Inc. generates revenue through the lease and sale of medical equipment, as well as the research, design, development, and manufacture of immune cell products. The company offers beauty cosmetics, skin care products, and daily necessities such as dental floss, chewing gum, chewing spray, and dry hair products. Its makeup series includes eye shadow gel, eye color palette, lip gloss, lipstick, and lip wax. The firm provides services like brand authorization, management consulting, property leasing, and medical equipment leasing under an experience charging model for care institutions and medical management. The company’s products target consumers in the beauty and healthcare sectors, with medical equipment leased to care institutions and medical management entities. Immune cell products are developed for medical applications, while beauty and daily necessity products cater to personal care markets. The firm’s service model combines brand authorization with property and equipment leasing to support operational experience in healthcare facilities. Lukas Biomedical’s revenue streams include direct sales of medical equipment, lease agreements for medical devices, and the sale of immune cell products, beauty cosmetics, and daily necessities. Care institutions and medical management companies are key clients for leasing services, while beauty product lines serve individual consumers and retail channels. The experience charging model integrates brand authorization and management consulting to enhance service offerings for healthcare providers. Lukas Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lukas Biomedical stock

Interest Coverage Ratio of Lukas Biomedical is -35.73 in 2024.

Interest Coverage Ratio of Lukas Biomedical changed from -14.61 to -35.73, representing a 144.57% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Interest Coverage Ratio Lukas Biomedical since 2006 – with annual values, charts, and detailed analysis.

The Interest Coverage ratio measures a company's ability to pay interest on its debt. Higher ratios indicate greater financial strength and lower default risk.

Interest Coverage = EBIT / Interest Expense

A 'good' varies by industry and company stage. On Eulerpool, you can compare Interest Coverage Ratio's Lukas Biomedical with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Lukas Biomedical

All Key Metrics — Lukas Biomedical